In 2023, Sumitomo Pharma conducted an environmental assessment and disclosed corporate waste management data in accordance with recognized sustainability reporting standards. The company provided a breakdown of its waste by type (hazardous vs non-hazardous) and treatment method (recovery vs disposal), enabling greater transparency into its waste handling and environmental practices.
Metric (tonnes) | 2024 | 2023 | 2022 | 2021 - 2017 |
---|---|---|---|---|
Total Waste Generated | 0000000 | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
Total Waste Recovered | 0000000 | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
Total Hazardous Waste Generated | 0000000 | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
Non-Hazardous Waste Disposed | 0000000 | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
This table provides a simplified preview of selected waste data points. To access the complete dataset with full disclosures and structure, create a free account to purchase the full dataset.
In 2023, Sumitomo Pharma generated a total of 7,760 metric tonnes of waste.
Of this amount, 82.74% of Sumitomo Pharma's total waste generated was recovered through methods such as recycling, reuse, or composting, while 0.1% was disposed of through landfilling, incineration, or combustion. The remaining 17.15% was either treated using unspecified methods or not clearly categorized.
In 2023, Sumitomo Pharma reported a total waste generation of 7,760 metric tonnes, of which 82.74% was recovered through recycling, reuse, or composting. This high recovery rate suggests that Sumitomo Pharma has implemented strong circular economy practices and actively prioritizes sustainable waste management.
Since 2021, Sumitomo Pharma's total waste generation increased by 25.51%, including a 63.13% increase in 2023, indicating a persistent upward trend that may reflect scaling operations, inefficiencies in resource use, or a lack of effective waste minimization practices.
Over the same period, Sumitomo Pharma's waste recovery rate increased by 8.46%, including a 14.36% rise in 2023, indicating growing emphasis on circularity and improved operational practices for diverting waste from disposal.
Overall, Sumitomo Pharma has seen a consistent rise in waste generation both over the long term and in the year 2023. However, the company has also steadily improved its waste recovery performance, suggesting that it is actively working to offset the environmental consequences of increased production through enhanced circularity efforts.
In 2023, Sumitomo Pharma generated a total of 7,760 metric tonnes of waste.
Of this amount, 85.34% of Sumitomo Pharma's total waste generated of was classified as hazardous waste, characterized by properties such as toxicity, flammability, corrosiveness, or reactivity that may pose risks to human health, ecosystems, or the environment. 14.66% was identified as non-hazardous waste, generally considered less harmful and subject to lighter regulatory controls.
Since 2021, Sumitomo Pharma's total waste generation increased by 25.51%, including a 63.13% rise in 2023, reflecting a persistent upward trend that could be linked to operational growth, inefficient material use, or limited investment in waste prevention systems.
Over the same period, the share of hazardous waste in Sumitomo Pharma's total output increased by 1.54%, including a further 12.67% rise in 2023, suggesting a troubling upward shift toward more environmentally harmful waste streams that could raise compliance costs and environmental risks.
Overall, Sumitomo Pharma has seen a continuous rise in both total waste and hazardous waste over time, signaling a worsening environmental impact that may require urgent reassessment of material sourcing, production processes, or waste mitigation strategies.